The total number of records retrieved from this search are 10. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_5422	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-3-1	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result64% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5423	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-3-1	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result40% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5424	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-3-1	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result17% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5425	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-8-5	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5426	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-8-5	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5427	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-8-5	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result35% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5553	Virus nameReovirus	Virus strainReovirus serotype 3	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineSKBR3	Concentration of cell line60% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration40 MOI	In-vitro resultCell viability drops from 93 to 16% after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS6994858
IDOV_5626	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman head and neck carcinoma cell line	Cell lineKB	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration4 pfu	In-vitro result50% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5824	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast carcinoma cell line	Cell lineSKBR3	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 pfu	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5846	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman head and neck carcinoma cell line	Cell lineKB	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration4 pfu	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578